Rezubio’s RZ-520 Enters Phase 1 After FDA and NMPA Clearances

Rezubio has dosed the first cohort in a Phase 1 study of RZ-520, an inhaled investigational therapy for chronic respiratory diseases, after securing clinical trial clearances from the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA). The study will assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers.

RZ-520 Enters First-in-Human Development

The first cohort dosing marks the transition of RZ-520 from preclinical development into clinical testing. The trial will provide the initial human data needed to characterize how the drug is tolerated and distributed, while also evaluating pharmacodynamic effects that could help establish an early clinical profile.

RZ-520 is the second clinical-stage candidate generated through Rezubio’s proprietary Membrane-Anchored Drug Design (MADD) platform. The company is developing the molecule as a locally acting inhaled therapy intended to maintain drug exposure in the lungs while limiting distribution into the systemic circulation.

That approach could be relevant in chronic respiratory diseases, where sustained activity at the site of disease may support therapeutic effects while reducing exposure to tissues outside the lung.

Local Lung Exposure Is Central to the Approach

Preclinical studies of inhaled RZ-520 showed robust therapeutic activity across multiple disease models, according to the company. The candidate also demonstrated a safety profile characterized by negligible systemic drug exposure in those studies.

RZ-520 therefore enters clinical development with a pharmacologic hypothesis centered on tissue targeting: maintaining prolonged local exposure in the lung while minimizing systemic exposure. Whether those characteristics translate into meaningful clinical advantages will depend on the Phase 1 PK, PD, and safety findings.

The company has not disclosed the specific validated target, mechanism of action, dose levels, number of planned cohorts, or detailed preclinical efficacy results in the information provided.

MADD Platform Expands Clinical Pipeline

Rezubio developed RZ-520 using its MADD platform, which engineers therapeutics for prolonged residence within specific tissues and optimized PK characteristics. The platform can target cell-surface proteins and is being applied to therapeutic programs in both the respiratory and gastrointestinal tracts.

The advancement of a second MADD-derived candidate into human studies provides an early clinical test of whether the platform can repeatedly generate drug candidates with differentiated tissue-exposure profiles.

Yusheng Xiong, CEO of Rezubio, said the dual FDA and NMPA clearances, together with first-cohort dosing, represent an important milestone for RZ-520 and the MADD platform. He also highlighted the company’s broader strategy of developing tissue-targeted therapies for difficult-to-treat diseases.

Phase 1 Will Establish the Human Profile

The immediate priority is to generate first-in-human safety and pharmacology data. Investigators will evaluate tolerability alongside PK and PD measures in healthy volunteers, establishing the exposure-response information needed to guide subsequent clinical development.

No clinical efficacy conclusions can yet be drawn from the program, and the company has not provided a timeline for Phase 1 completion or disclosed plans for later-stage studies.

If RZ-520 reproduces its preclinical lung-targeting and limited systemic-exposure characteristics in humans, the Phase 1 program could provide an important proof of concept for Rezubio’s MADD platform and support further development in chronic respiratory diseases.

Reference

Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a Novel Inhaled Therapy for Chronic Respiratory Diseases | Rezubio Sept 2026